People with rare genetic diseases face challenges accessing CRISPR gene-editing technologies due to high costs and small market sizes, hindering development of personalized therapies.
Emerging treatments like Casgevy for sickle-cell disease and β-thalassaemia face limited adoption due to prohibitive costs, further restricting access to potentially life-saving therapies.
[
add
]
[
|
|
...
]